Updated:
The J. Baker Foundation
The J. Baker Foundation was formed in August 2013 by brothers Julian and Felix Baker, the co-founders of Baker Bros. Advisors LP. The Baker brothers built...
The J. Baker Foundation
The J. Baker Foundation was formed in August 2013 by brothers Julian and Felix Baker, the co-founders of Baker Bros. Advisors LP. The Baker brothers built their wealth through a highly focused, long-duration public and private biotech investment strategy that generated outsized returns from concentrated bets on companies like Seattle Genetics, Genomic Health, and Incyte. The foundation translates that concentrated financial capital into charitable capital for a narrow set of causes, primarily higher education, healthcare innovation, food security, and educational access. Unlike many major foundations that build large internal program staffs, the Bakers run the foundation with the operational footprint of a family office, making grants to a curated list of institutions rather than issuing broad requests for proposals. The foundation does not disclose its grantmaking by dollar amount, but Altss estimates total assets of roughly $66 million based on public filings. The foundation's grantmaking pattern closely mirrors the Bakers' intellectual interests—historic gifts have supported Harvard University, where Julian Baker serves on the Board of Overseers, and Cold Spring Harbor Laboratory, a leading biomedical research institution. The foundation also directs capital toward food-security nonprofits, reflecting a secondary philanthropic priority that extends beyond the life-sciences focus of Baker Bros. Advisors. The foundation does not make program-related investments, mission-related investments, or participate in any co-investment structures—uncharacteristic of many large foundations that blur the line between endowment management and grantmaking. The foundation operates with minimal public-facing infrastructure. It maintains no dedicated website, does not publish an annual report, and employs no known professional staff beyond the principals themselves. In May 2024, the foundation disclosed its 2023 IRS Form 990-PF, the primary public window into its activities, confirming a continued pattern of grants to a compact roster of educational and healthcare institutions (per public record, 2024). This opacity is deliberate and mirrors the culture of Baker Bros. Advisors, which has historically communicated with investors through brief quarterly letters and rarely grants media interviews. Structurally, the foundation is distinct from most biotech-wealth philanthropic vehicles in its refusal to accept unsolicited proposals. This is not a foundation that sees itself as a public grantmaking institution—it functions more like a private giving vehicle for two investors who apply the same research rigor and concentration to their charitable giving that they apply to their portfolio. There is no pledge to spend down by a certain date, no public-facing DEI overlay, and no advisory board of external experts. The foundation remains a direct expression of the Baker brothers' intellectual priorities, with no known succession plan for grantmaking governance beyond the founding generation.
General information
Firm type
Endowment / Foundation
Year founded
2013
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Julian Baker
Co-Founder
Felix Baker
Co-Founder
Sector focus
Frequently asked questions
Who runs investment decisions at the J. Baker Foundation?
The foundation does not maintain a dedicated chief investment officer or internal investment staff. Its portfolio is likely managed conservatively, given its modest $66 million asset base (Altss estimate) and the absence of any program-related or mission-related investment activity in public filings. The Baker brothers themselves, through Baker Bros. Advisors, likely oversee the foundation's investment posture, but the corpus is small relative to the multibillion-dollar hedge fund they run, making it a minor administrative task rather than a separate investment operation.
How is the J. Baker Foundation related to Baker Bros. Advisors?
The foundation is entirely separate from Baker Bros. Advisors LP, the biotech-focused hedge fund that generated the Baker brothers' wealth. There is no known commingling of assets, shared staff, or program-related investments that would blur the line between the for-profit fund and the charitable entity. The foundation's grantmaking does not fund companies in which Baker Bros. holds positions, a critical structural separation that avoids self-dealing concerns common in hedge-fund-affiliated foundations.
Does the J. Baker Foundation accept unsolicited grant proposals?
No. The foundation explicitly restricts its grantmaking to preselected charitable organizations and does not accept unsolicited requests for funds. This policy sets it apart from most private foundations, which typically maintain a formal application process. The list of recipients is compact and stable, with no indication that new organizations are added through open competition.
Where does the underlying wealth come from?
The wealth originates from Julian and Felix Baker's management of Baker Bros. Advisors LP, one of the most concentrated and successful biotech hedge funds globally. The firm is known for making large, long-duration equity investments in a small number of biotechnology companies and holding those positions through clinical and regulatory volatility. Notable historic investments include Seattle Genetics and Incyte, which generated multibillion-dollar returns over holding periods measured in decades (per public record).
What institutions receive grants from the J. Baker Foundation?
Historic grant recipients include Harvard University, where Julian Baker serves on the Board of Overseers, and Cold Spring Harbor Laboratory, a leading biomedical research institution. The foundation also supports food-security and educational-access nonprofits. Because the foundation does not publish a grantee list or annual report, the full roster is known only through IRS Form 990-PF disclosures, which typically lag by at least one year.
Does the foundation have any paid staff or a physical office?
Public filings indicate no paid professional staff, no dedicated office space beyond the registered New York address, and no published contact information. The foundation appears to be administered directly by the Baker brothers or their immediate support infrastructure, consistent with the lean operational posture the brothers maintain across their professional activities.
Is the foundation likely to grow significantly in the near term?
The foundation's growth trajectory depends entirely on additional contributions from the Baker brothers, who remain active in managing Baker Bros. Advisors. Given the hedge fund's concentrated public-equity strategy and the brothers' ability to generate periodic windfalls from biotech M&A and drug approvals, the foundation's corpus could increase materially in any given year—but the brothers have made no public pledge or commitment to scale the foundation to a specific size.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: